HLF and acute lymphoblastic leukemia: Interestingly, 1 sCD79b– PDX-sample exposing a distinct population of sCD79b+ cells (6.8% sCD79b+ cells, E2A-HLF+ BCP-ALL) displayed substantial response and survival prolongation upon PolVed therapy (Figure 2G, Suppl.